Petros Tzimas1, Maria Tsoumani2, Dimitrios Giannakis3, Kallirroi Kalantzi2, Anastasios Petrou4, Vasileios Chantzichristos2, Nikolaos Sofikitis3, Georgios Papadopoulos4, Haralampos Milionis2, Alexandros Tselepis2. 1. Department of Anesthesiology and Postoperative Intensive Care, Faculty of Medicine, School of Health Sciences, University of Ioannina, University Campus, 45110, Ioannina, Greece. petzimas@gmail.com. 2. Department of Chemistry, Laboratory of Biochemistry, Atherothrombosis Research Centre, University of Ioannina, Ioannina, Greece. 3. Department of Urology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece. 4. Department of Anesthesiology and Postoperative Intensive Care, Faculty of Medicine, School of Health Sciences, University of Ioannina, University Campus, 45110, Ioannina, Greece.
Abstract
OBJECTIVES: The objective of this study was to test platelet function pre- and peri-operatively in clopidogrel-treated patients undergoing transurethral resection of the prostate. METHODS: This was a pilot study involving 20 male patients treated with clopidogrel (75 mg/day) for the secondary prevention of cardiovascular disease and scheduled for elective transurethral resection of the prostate. Platelet function testing with light transmittance aggregometry in platelet-rich plasma of four samples (T0, T1, T2, and T3 drawn on the same day, 3 and 7 days of clopidogrel cessation and 24-h post-operatively, respectively) was performed and evaluated in each patient. P-selectin membrane expression was evaluated using monoclonal antibodies. RESULTS: The platelet response to adenosine diphosphate 5 µΜ and 20 µΜ at T0 were 42 ± 15 and 60 ± 14%, respectively. After discontinuation of clopidogrel, corresponding maximum aggregation values at T1 were 60 ± 16 and 74 ± 14%, and increased to 69 ± 16 and 79 ± 18% at T2. No significant difference in platelet aggregation values were noted between T1 and T2, while similar aggregation values were recorded at T3. CONCLUSIONS: Our findings indicate that in patients undergoing transurethral resection of the prostate, platelet activation is similar 3 and 7 days from clopidogrel cessation. These results may be of relevance in subjects at increased thrombotic risk prior to a surgical procedure carrying a high-bleeding risk.
OBJECTIVES: The objective of this study was to test platelet function pre- and peri-operatively in clopidogrel-treated patients undergoing transurethral resection of the prostate. METHODS: This was a pilot study involving 20 male patients treated with clopidogrel (75 mg/day) for the secondary prevention of cardiovascular disease and scheduled for elective transurethral resection of the prostate. Platelet function testing with light transmittance aggregometry in platelet-rich plasma of four samples (T0, T1, T2, and T3 drawn on the same day, 3 and 7 days of clopidogrel cessation and 24-h post-operatively, respectively) was performed and evaluated in each patient. P-selectin membrane expression was evaluated using monoclonal antibodies. RESULTS: The platelet response to adenosine diphosphate 5 µΜ and 20 µΜ at T0 were 42 ± 15 and 60 ± 14%, respectively. After discontinuation of clopidogrel, corresponding maximum aggregation values at T1 were 60 ± 16 and 74 ± 14%, and increased to 69 ± 16 and 79 ± 18% at T2. No significant difference in platelet aggregation values were noted between T1 and T2, while similar aggregation values were recorded at T3. CONCLUSIONS: Our findings indicate that in patients undergoing transurethral resection of the prostate, platelet activation is similar 3 and 7 days from clopidogrel cessation. These results may be of relevance in subjects at increased thrombotic risk prior to a surgical procedure carrying a high-bleeding risk.
Authors: Victor A Ferraris; Daniel L Davenport; Sibu P Saha; Alethea Bernard; Peter C Austin; Joseph B Zwischenberger Journal: Ann Thorac Surg Date: 2011-04-23 Impact factor: 4.330
Authors: James D Douketis; Alex C Spyropoulos; Scott Kaatz; Richard C Becker; Joseph A Caprini; Andrew S Dunn; David A Garcia; Alan Jacobson; Amir K Jaffer; David F Kong; Sam Schulman; Alexander G G Turpie; Vic Hasselblad; Thomas L Ortel Journal: N Engl J Med Date: 2015-06-22 Impact factor: 91.245
Authors: A Kouki; J V Mitsios; M Sakarellos-Daitsiotis; C Sakarellos; A D Tselepis; V Tsikaris; D C Tsoukatos Journal: J Thromb Haemost Date: 2005-08-26 Impact factor: 5.824
Authors: Grant W Reed; Amit Kumar; Jianping Guo; Sary Aranki; Prem Shekar; Arvind Agnihotri; Andrew O Maree; Dalton S McLean; Kenneth Rosenfield; Christopher P Cannon Journal: Clin Cardiol Date: 2015-02-05 Impact factor: 2.882
Authors: Matthew J Price; James S Walder; Brian A Baker; Darell E Heiselman; Joseph A Jakubowski; Douglas K Logan; Kenneth J Winters; Wei Li; Dominick J Angiolillo Journal: J Am Coll Cardiol Date: 2012-06-19 Impact factor: 24.094
Authors: Emma C Hansson; Lena Jidéus; Bengt Åberg; Henrik Bjursten; Mats Dreifaldt; Anders Holmgren; Torbjörn Ivert; Shahab Nozohoor; Mikael Barbu; Rolf Svedjeholm; Anders Jeppsson Journal: Eur Heart J Date: 2015-09-01 Impact factor: 29.983